NDC 73309-008-02 - Imatinib Mesylate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 73309-008
- Requested NDC
- 73309-008-02
- Package NDCs from labels
- 73309-008-01, 73309-008-02, 73309-008-03, 73309-008-04
- Manufacturer
- BLUEBAY SHANDONG CO.,LTD
- Effective date
- 2020-12-02
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Imatinib Mesylate - BLUEBAY SHANDONG CO.,LTD | BLUEBAY SHANDONG CO.,LTD | 2020-12-02 | BULK INGREDIENT |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 73309-008-01 | Imatinib Mesylate | 500 g in 1 JAR | POWDER | 500 | 3 | |
| 73309-008-02 | Imatinib Mesylate | 1900 g in 1 JAR | POWDER | 1900 | 3 | |
| 73309-008-03 | Imatinib Mesylate | 1000 g in 1 JAR | POWDER | 1000 | 3 | |
| 73309-008-04 | Imatinib Mesylate | 900 g in 1 JAR | POWDER | 900 | 3 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Imatinib Mesylate | IMATINIB MESYLATE | Apotex Corp | 0291eca5-7a1d-4a79-30be-252224d96509 | 2026-09-08 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB MESYLATE | QUALLENT PHARMACEUTICALS HEALTH LLC | a819a954-41c9-4d49-a74e-c8c4b338b22a | 2026-08-27 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB MESYLATE | Major Pharmaceuticals | 7c037022-7fc8-4b6e-9db3-427206c572b4 | 2026-08-04 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB MESYLATE | Aurobindo Pharma Limited | a4e409f7-20b4-4c80-8a6a-f95995ffad78 | 2026-07-28 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB | Mylan Pharmaceuticals Inc. | a1787fad-3612-43e1-98fa-ce62361e0b3c | 2026-07-15 | Warnings, Adverse reactions | 8A1O1M485B |
| Gleevec | IMATINIB MESYLATE | Novartis Pharmaceuticals Corporation | 211ef2da-2868-4a77-8055-1cb2cd78e24b | 2026-07-13 | Warnings, Adverse reactions | 8A1O1M485B |
| IMATINIB MESYLATE | IMATINIB MESYLATE | Civica Script LLC | 9fc5ec7b-98c4-4b1a-890c-be1343177dbd | 2026-07-03 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB | Golden State Medical Supply, Inc. | 9131b2ce-752d-3a30-e053-2a95a90adaab | 2026-06-16 | Warnings, Adverse reactions | 8A1O1M485B |
| imatinib mesylate | IMATINIB MESYLATE | Sun Pharmaceutical Industries, Inc. | 07764bf9-21b4-4e32-9d7e-e348f8e4291f | 2026-06-01 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB | Safecor Health, LLC | f4acacbd-13f8-4a46-b615-b639a17f331f | 2026-04-17 | Warnings, Adverse reactions | 8A1O1M485B |
| imatinib mesylate | IMATINIB MESYLATE | Upsher-Smith Laboratories, LLC | 5d07ac08-962e-41a8-8a3c-50febc8c5f34 | 2026-01-09 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB MESYLATE | Chartwell RX, LLC | 65b4d8a6-349d-4fb1-9818-dad6b4ad4fa1 | 2025-12-10 | Warnings, Adverse reactions | 8A1O1M485B |
| IMATINIB MESYLATE | IMATINIB MESYLATE | Camber Pharmaceuticals, Inc. | e97f0238-b9da-46af-83a3-0826e39893e8 | 2025-11-25 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB | Mylan Institutional Inc | 1debf3a0-7587-47d7-8ea6-e739698d7297 | 2025-09-15 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib Mesylate | IMATINIB MESYLATE | American Health Packaging | 6e7ed4ef-24e3-4545-9a99-2e34c946e8e7 | 2025-02-19 | Warnings, Adverse reactions | 8A1O1M485B |
| IMKELDI | IMATINIB ORAL | Shorla Oncology Inc., | 26658bb7-9ba1-a10e-e063-6394a90a172e | 2024-12-05 | Warnings, Adverse reactions | 8A1O1M485B |
| imatinib mesylate | IMATINIB MESYLATE | Qilu Pharmaceutical Co., Ltd. | 82eb01e0-8685-4f06-8a72-7663e8ded38f | 2024-12-04 | Warnings, Adverse reactions | 8A1O1M485B |
| imatinib mesylate | IMATINIB MESYLATE | BluePoint Laboratories | be5b9047-155b-59ca-e053-2995a90ad3dc | 2023-09-21 | Warnings, Adverse reactions | 8A1O1M485B |
| imatinib mesylate | IMATINIB MESYLATE | Archis Pharma LLC | 9de8d8b9-cf88-4960-82b7-89e5ceb7720e | 2023-09-21 | Warnings, Adverse reactions | 8A1O1M485B |
| Imatinib mesylate 400 mg | IMATINIB MESYLATE | Armas Pharmaceuticals Inc. | 7b7cc194-29e4-4484-a364-a1ac7d7d6cf5 | 2019-03-08 | Warnings, Adverse reactions | 8A1O1M485B |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.